Andrew Schiermeier

Andrew Schiermeier is a declared insider of Intellia Therapeutics, Inc., with filings sourced from SEC (Form 4). The record holds 5 filings, for trades running from 6 March 2019 to 5 January 2021.

On the open market, the record shows 2 purchases worth €104k and 1 sale worth €63k. Netting one side against the other leaves €41k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 option exercises. Since January 2021: no purchases and 1 sale on the market.

The newest entry dates from 5 January 2021: an option exercise, in Intellia Therapeutics, Inc. The clock since the last published purchase (12 March 2019) now reads 2,782 days. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.